Wall Street analyst estimates for Abeona Therapeutics Inc. (ABEO): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-0.17 | ||
| 2026-08-13 | $-0.35 | $-0.23 | -51.1% |
| 2026-05-13 | $-0.30 | $-0.33 | +9.1% |
| 2026-03-17 | $-0.34 | $-0.35 | +2.9% |
| 2025-11-12 | $-0.10 | $-0.27 | +63.0% |
| 2025-08-11 | $1.71 | $-0.39 | +538.5% |
| 2025-05-14 | $-0.24 | $-0.35 | +31.4% |
| 2025-03-20 | $-0.24 | $-0.35 | +31.0% |
Valuation Ratios
| Price / Book | 2.39 |
| EV / EBITDA | -3.81 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $889000 | $837000 | $3.0M | 0 | $10.0M | $3.0M | $1.4M | $3.5M | 0 | $5.8M |
| Cost of Revenue | $10.7M | $17.0M | $38.7M | $48.6M | 0 | 0 | $450000 | $1.6M | $2.9M | $1.5M |
| Gross Profit | -$9.8M | -$16.2M | -$35.7M | -$48.6M | $10.0M | $3.0M | $964000 | $1.9M | -$2.9M | $4.3M |
| Research & Development | $10.7M | $17.0M | $38.7M | $53.8M | $30.1M | $38.7M | $29.0M | $31.1M | $34.4M | $26.8M |
| Selling, General & Admin | $13.3M | $10.9M | $20.1M | $20.7M | $23.8M | $21.6M | $17.3M | $19.0M | $29.9M | $65.0M |
| Operating Expenses | $24.8M | $28.7M | $61.2M | $28.5M | $91.4M | $92.8M | $51.9M | $49.0M | $61.3M | $93.7M |
| Operating Income | -$23.9M | -$27.8M | -$58.2M | -$77.1M | -$81.4M | -$89.8M | -$50.9M | -$47.1M | -$64.2M | -$89.4M |
| EBITDA | -$21.0M | -$26.6M | -$54.3M | -$69.3M | -$74.5M | -$76.8M | -$34.4M | -$50.6M | -$56.6M | $78.6M |
| Interest Expense | $6000 | $8000 | $11000 | $400000 | $4.1M | $3.7M | $736000 | $418000 | $4.2M | $3.7M |
| Pre-tax Income | -$21.9M | -$27.3M | -$56.7M | -$76.3M | -$84.2M | -$84.9M | -$39.7M | -$54.2M | -$63.7M | $71.3M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $100000 |
| Net Income | -$21.9M | -$27.3M | -$56.7M | -$76.3M | -$84.2M | -$84.9M | -$39.7M | -$54.2M | -$63.7M | $71.2M |
| EPS | $-16.00 | $-16.40 | $-29.81 | $-38.07 | $-22.75 | $-21.50 | $-5.53 | $-2.53 | $-1.55 | $1.34 |
| EPS (Diluted) | $-16.00 | $-16.40 | $-29.81 | $-38.07 | $-22.75 | $-21.50 | $-5.53 | $-2.53 | $-1.55 | $1.01 |
| Shares Outstanding (Diluted) | $1.4M | $1.7M | $1.9M | $2.0M | $3.7M | $3.9M | $7.9M | $21.4M | $41.0M | $66.1M |
Price
| Price | $5.37 |
| Market Cap | $306M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ARCT · ASMB · ELDN · FHTX · HUMA · PBYI · SGMT
Explore sector: Healthcare · Biotechnology
More sections of ABEO: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks